Drug Efficacy, Safety, and Biologics Discovery
168,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
84 °P sammeln
  • Gebundenes Buch

Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools covers key emerging technologies in pharmaceutical R & D and how they have substantially impacted (or are currently impacting) drug discovery. The cross disciplinary collaborations implicit in integrating these technologies with drug discovery operations will fuel the engine for future innovations. This book cuts across the multiple areas of drug discovery, each chapter authored by pioneers in that field, making for a broad appeal to the chemical and biological scientists and technologists involved in drug discovery and development.…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools covers key emerging technologies in pharmaceutical R & D and how they have substantially impacted (or are currently impacting) drug discovery. The cross disciplinary collaborations implicit in integrating these technologies with drug discovery operations will fuel the engine for future innovations. This book cuts across the multiple areas of drug discovery, each chapter authored by pioneers in that field, making for a broad appeal to the chemical and biological scientists and technologists involved in drug discovery and development.
Autorenporträt
Sean Ekins, MSc, PHD, DSc, is the Principal at Collaborations in Chemistry; and Adjunct Associate Professor in the Department of Pharmaceutical Sciences at the University of Maryland, School of Pharmacy. Dr. Ekins has published widely on ADME/Tox, systems biology, computational, and in vitro drug discovery approaches. He has previously edited two Wiley books: Computer Applications in Pharmaceutical Research and Development (2006) and Computational Toxicology: Risk Assessment for Pharmaceutical and Environmental Chemicals (2007). Jinghai J. Xu, PHD, is Director of Automated Biotechnology at Merck. Previously he headed predictive toxicology at Pfizer, where he led research activities in drug-induced liver injury, genetic toxicology, drug transporters, assay development, high content screening, in vitro in vivo correlations, systems biology, and systems toxicology. Dr. Xu has served on steering committees of academic-industry and industry-industry collaborations, and as a guest lecturer at the Massachusetts Institute of Technology.